MRNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Moderna Inc (MRNA) is not a strong buy at the moment for a beginner investor with a long-term horizon. The stock faces significant headwinds, including declining revenue, net income, and EPS, alongside insider and hedge fund selling. While there are some positive developments in its vaccine pipeline, the financial challenges and lack of clear bullish momentum make it prudent to hold off on investment for now.
The technical indicators show a neutral to slightly bearish trend. The MACD histogram is negative (-0.517), indicating bearish momentum, while RSI at 59.338 is neutral. The stock is trading near its pivot level of 53.089, with resistance at 55.504 and support at 50.675. No strong upward momentum is evident.
Moderna is advancing its vaccine portfolio, including a flu vaccine seeking U.S. approval and promising results from its personalized cancer vaccine. Gross margin increased by 25.51% YoY, showing operational efficiency.
The stock has a 70% chance of declining in the next week and month based on historical patterns.
In Q4 2025, revenue dropped by 29.81% YoY to $678M. Net income declined by 26.25% YoY to -$826M, and EPS fell by 26.99% to -2.11. Despite these declines, gross margin improved to 54.57%, up 25.51% YoY.
Analysts are mixed to bearish. BofA and Citi highlight the $2.3B settlement with Arbutus as a partial resolution to litigation but not an outright win. Price targets range from $30 to $69, with most analysts maintaining Neutral or Underperform ratings.
